SCHEMBL4251404

SCHEMBL4251404

COC(=O)c1cnc(C)[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 1/20 0.50
▸ BAZ2B Q9UIF8 1/20 0.50
▸ MAPK1 P28482 3/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ GLA P06280 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPT P10636 2/20 0.39
▸ XDH P47989 1/20 0.39
▸ ALPL P05186 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ ABL1 P00519 3/20 0.38
▸ SRC P12931 2/20 0.38
▸ ROCK1 Q13464 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8818379 0.81 ALDH1A1 (0.47) BAZ2BCYP1A2KDM4EGLAGAA
SCHEMBL8653202 0.79 MMP2 (0.47) MMP2BAZ2BKDM4ETSHRMAPT
SCHEMBL2254056 0.79 KDM4E (0.50) MMP2MAPK1CYP1A2KDM4EGLA
SCHEMBL11392770 0.78 MMP2 (0.49) MMP2MAPK1CYP1A2KDM4EGLA
SCHEMBL20534022 0.78 MMP2 (0.49) MMP2MAPK1CYP1A2KDM4EGLA
SCHEMBL24415499 0.78 MMP2 (0.49) MMP2MAPK1CYP1A2KDM4EGLA
SCHEMBL18626490 0.78 MMP2 (0.49) MMP2BAZ2BMAPK1CYP1A2KDM4E
SCHEMBL10126219 0.78 BAZ2B (0.44) MMP2BAZ2BKDM4EGAAMAPT
SCHEMBL889035 0.77 — —
SCHEMBL889025 0.77 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023107597-A2 BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS AND USES THEREOF Kineta, Inc. (US) 2023-06-15 — — WO disclosed
CN-107074857-A Method for preparing crystallization organic semiconducting materials 巴斯夫欧洲公司 2017-08-18 — — CN disclosed
CN-107004768-A Organic semiconductor composition containing a liquid medium 巴斯夫欧洲公司 2017-08-01 — — CN disclosed
EP-2991989-B1 IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS PFIZER (US) 2017-06-28 — — EP disclosed
EP-2991989-B1 IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS PFIZER (US) 2017-06-28 — — EP disclosed
US-9296761-B2 Triazine derivatives PFIZER INC. (US) 2016-03-29 — — US disclosed
US-9296761-B2 Triazine derivatives PFIZER INC. (US) 2016-03-29 — — US disclosed
US-9296761-B2 Triazine derivatives PFIZER INC. (US) 2016-03-29 — — US disclosed
EP-2991989-A1 IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS Pfizer Inc. (US) 2016-03-09 — — EP disclosed
US-20150353579-A1 Triazine Derivatives PFIZER (US) 2015-12-10 — — US disclosed
WO-2014177977-A1 IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS PFIZER INC. (US) 2014-11-06 — — WO disclosed
US-20140329820-A1 Triazine Derivatives PFIZER INC. (US) 2014-11-06 — — US disclosed
WO-2014177977-A1 IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS PFIZER INC. (US) 2014-11-06 — — WO disclosed
US-20140329820-A1 Triazine Derivatives PFIZER INC. (US) 2014-11-06 — — US disclosed
EP-2083816-A2 HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Brystol-Myers Squibb Company (US) 2009-08-05 — — EP disclosed
WO-2008057775-A2 HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-15 — — WO disclosed
CN-1101384-C Process for preparing 1-biphenylmethylimidazole derivatives SANKYO CO (JP) 2003-02-12 — — CN disclosed
CN-1051766-C Angiotensin II antagonist imidazole derivatives, their preparation and their theapeutic use SANKYO CO (JP) 2000-04-26 — — CN disclosed
CN-1045770-C Process for preparing 1-biphenylmethylimidazole derivatives SANKYO CO (JP) 1999-10-20 — — CN disclosed
CN-1189490-A Process for preparing 1-biphenylmethylimidazole derivatives SANKYO CO (JP) 1998-08-05 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329820-A1 Triazine Derivatives PDE12, PDE5A, PDE10A MMP2 380/4885BAZ2B 103/4885MAPK1 2762/4885
US-20150353579-A1 Triazine Derivatives PDE12, PDE5A, PDE10A MMP2 380/4885BAZ2B 103/4885MAPK1 2762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback